NASDAQ: BLRXBiolinerx Ltd Stock
$0.51-0.01 (-1.92%)
Updated Oct 3, 2024
BLRX Price
$0.51
Fair Value Price
$0.40
Market Cap
$40.52M
52 Week Low
$0.50
52 Week High
$1.93
P/E
-16.83x
P/B
2.9x
P/S
2.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.05M
Earnings
-$30.12M
Gross Margin
64.5%
Operating Margin
-159.55%
Profit Margin
-176.7%
Debt to Equity
3.62
Operating Cash Flow
-$30M
Beta
0.69
Next Earnings
Nov 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BLRX Overview
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLRX ($0.51) is overvalued by 27.77% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BLRX ($0.51) is not significantly undervalued (27.77%) relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLRX due diligence checks available for Premium users.
Be the first to know about important BLRX news, forecast changes, insider trades & much more!
BLRX News
Valuation
BLRX fair value
Fair Value of BLRX stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$0.40
Overvalued by
29.04%
BLRX ($0.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLRX ($0.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.83x
Industry
-109.51x
Market
26.22x
BLRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.9x
Industry
5.92x
BLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLRX's financial health
Profit margin
Revenue
$5.4M
Net Income
$484.0k
Profit Margin
9%
BLRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.6M
Liabilities
$50.6M
Debt to equity
3.62
BLRX's short-term assets ($49.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLRX's short-term assets ($49.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.3M
Investing
-$8.6M
Financing
$23.9M
BLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLRX vs Biotech Stocks
Biolinerx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.